Niosomal Carriers for Diabetic Management: A Novel Approach

Diabetes mellitus is a chronic metabolic disorder currently a highly concerning health topic due to increased prevalence and lack of complete cure. conventional therapies such as oral hypoglycaemic agents and insulin injections are effective to combat increased insulin levels but suffer from poor bioavailability and side effects. hence in recent years nanotechnology-based drug delivery systems have gained a lot of attention as potential tool for overcoming the limitations of traditional therapies. niosomes are one among the nanotechnology-based approaches that can act as promising carrier for various therapeutic agents. Niosomes are non-ionic surfactant vesicles that can encapsulate and deliver drugs, offering improved bioavailability and targeted delivery for managing diabetes. Niosomal systems not only enhance the pharmacokinetic profile of drugs like metformin, Glibenclamide, and insulin but also allow for alternative administration routes such as transdermal and oral, reducing the need for invasive injections. Furthermore, co-encapsulation of antioxidants or anti-inflammatory agents with antidiabetic drugs may provide synergistic effects beneficial for long-term management of diabetes and its complications. This review explores the recent advancements in niosomal drug delivery systems for diabetic management, discussing formulation strategies, therapeutic outcomes, challenges, and future perspectives in the development of niosome-based antidiabetic therapies.